NewalR&D Ltd

Please let me introduce you to NewalR&D Ltd and therapeutic ezrin peptides. Newal R&D Ltd, based in Central London, is developing ezrin-peptide therapeutic-breakthroughs in human health, based on patent protected and innovative platform technology, which has already been clinically demonstrated in one commercial territory.
NewalR&D is seeking £5 million under HMRC EIS Advanced Assurance at a pre-money value of £13.1 million. We hope for at least a 10X uplift in value from Series A to the public market exit. I invite you to invest in NewalR&D Ltd, to progress the ezrin peptide pharmaceutical break-through.
1. NewalR&D Limited
Newal R&D is a new immune-pharmaceutical company based in central London, developing Generation-3 and Generation-4 synthetic ezrin peptide products for world pharmaceutical markets, for the treatment of all sexually transmitted infections as a one-stop therapy. NewalR&D is also developing ezrin peptides for the treatment of age-related chronic inflammatory diseases, as well as for the treatment of Long COVID and COVID-vaccine injury.
The ambition of NewalR&D is to grow a profitable global pharmaceutical business with a turnover exceeding one billion dollars. NewalR&D is unique in that the product registration development program is de-risked by the know-how from the launch of a safe and effective Generation-1 ezrin peptide product on the Russian market.
2. Management
Dr Rupert Holms, CEO of NewalR&D, is the world-expert on ezrin peptide technology, and the founder & former executive chairman of profitable 120 million Euro turn-over (in roubles) Nearmedic in Russia. Dr John Abeles, Chairman of NewalR&D, is a veteran biotech founder & financier in the USA. NewalR&D is currently seeking talented management in all relevant fields.
3. Business Plan
Ezrin peptide therapy has many medical applications. However, we have decided to focus on the treatment of all Sexually Transmitted Infections (STIs), particularly Chlamydia, because this is the shortest path to product registration and sales. Once an ezrin peptide product is on the market, additional indications can be clinically tested and added to the approved medical applications for this class of pharmaceutical.
The cost of peptide manufacturing is relatively cheap, so the cost of an effective course of Sexually Transmitted Infection (STI) treatment could be priced below £99, allowing for mass market OTC sales. In addition, it is possible to achieve 90% gross margins, leading to significant positive cash-flow and an attractive ROI.
NewalR&D aims to reach out to international markets via licensing and partnerships. Ezrin peptide products for other treatment applications in the age-related inflammatory disease area and the Long COVID / COVID vaccine injury field, shall probably be licensed out to major partners.
We are seeking local operational business partners and major multi-national licensees for world-wide development, particularly in USA, Japan, China and SE Asia.
In the UK, we shall use subcontractors to develop and register products. For example, we need to register the active pharmaceutical ingredient (API) and also develop the final product forms (sprays, syringes, pills etc). We can also use peptide manufacturers in the USA, UK, EU and China to serve local markets, then backward integrate into investing in our own manufacturing to improve margins, and later forward integrate into distributors.
From my experience in start-up companies, we may receive some milestone payments from large licensees, but not necessarily continuous licensing income streams. I believe Newal R&D needs multiple sources of income and be in control of its own cash flow. International tensions, sanctions and wars, mean that we should build local integrated businesses, not one business dependent on long supply chains. We also want to avoid getting into Master – Slave business relationships with much larger partners.
In summary: (and subject to all the usual unknowns & uncertainties about the future) The projected business plan and budget is as follows.
FROM 2023 to 2026, Newal R&D develops a portfolio of ezrin peptide products available for out-licensing and one ezrin peptide product is developed to market authorization by MHRA for UK sales. There is an IPO opportunity in 2027 or 2028.
FROM 2027 to 2031, NewalR&D may receive significant milestone payments from corporate partners. Newal R&D shall also launch an STI treatment product in the UK, with all the production, launch and promotion costs; to achieve growing sales and market penetration. I believe Newal R&D should invest its cash flow in further significant product developments. Post-IPO, NewalR&D should also invest in a major CAPEX program to build physical facilities for in-house product development, manufacturing and marketing.
FROM 2032 and on, sales compound, and significant Net Profits are generated, and the company should return 15% of Net Profit to shareholders. By 2036, the sales & licensing income is projected around one billion pounds, with a net profit around £400 million and dividends of £60 million.
4. Patents and Know-How
Small synthetic ezrin peptides are protected by granted patents world-wide. NewalR&D has granted patents in all significant commercial territories that provide exclusivity for Generation-3 ezrin peptides to 2036, plus there is secret Generation-4 know-how that can be converted to patents, to extend intellectual property protection to the 2050s.
5. The Sexually Transmitted Infection (STI) Problem
There is a pandemic of sexual infection developing due to changes in social behaviour (women are having more sex partners in a lifetime) and mutant infections are evolving drug & vaccine resistance. World-wide, 1.4 billion people are suffering a sexually
transmitted infection. In 2021 there were four million people diagnosed with an STI symptom in the UK, about a quarter of the sexually active population. There is a potential global commercial treatment market of at least 10 billion dollars.
6. Ezrin Peptide Solution to STIs
We have already clinically demonstrated that it is possible to knock-out any sexually transmitted infection (STI) with an easy to use and safe ezrin peptide product, in a short 5 day course of treatment.
Intravaginal, intrarectal and oral administrations of ezrin peptides, as short 5 day courses of treatment, can stop ALL STIs, by amplification of adaptive immunity of the mucosa while inhibiting inflammation. Ezrin peptides cure common urogenital problems such as chronic candida and chlamydia (cystitis), as well as serious infections such as HPV ( the cause of cervical cancer) and syphilis.
Ezrin peptide therapy is a paradigm shift in STI treatment: ezrin peptides can effectively treat and cure (in approximately ninety per cent of cases) ALL types of Sexually Transmitted Infection, whether viral, bacterial, fungal or protozoan, by amplification of adaptive immune responses.
The development strategy of NewalR&D is to rapidly develop and register an ezrin peptide RepG3 based product for vaginal delivery as a one-stop solution for all sexually transmitted infections, which also induces immune protection from relapse and re-infection.
At NewalR&D in London, we have chosen to focus on the development of ezrin peptides for treatment of STIs, because the clinical trials are of short-duration, the end-points are clear, so we hope to make rapid progress to product approvals and to market. The rapid response to a 5 day course of treatment with ezrin peptides, measured in a Day-10 and Day-30 follow-up, mean clinical trials are relatively cheap.
7. Ezrin Peptide Production
Ezrin peptides are short 5 to 14 amino-acid alpha-helical synthetic-peptides mimicking the Alpha domain of human ezrin. High quality peptide manufacturing is available in the UK through sub-contractors, so minimal upfront capital investment in production is required prior to commencement of clinical development. A course of treatment is likely to be between 6mg to 10mg of ezrin peptide (2mg per day). The cost of manufacturing at pilot scale is about one pound per milligram, but there are significant cost savings at high volume production.
8. Ezrin Peptides: Safety & Biological Activities
Small synthetic ezrin peptides have been clinically demonstrated safe: over more than two decades in more than 200,000 people in Russia (HEP-1 brand name “Gepon”) and there have been no adverse event reports.
Ezrin peptides have a unique combination of biological activities: inhibition of inflammation ( by the down-regulation of expression of IL-1b, IL-6, IL-8 and TNFa) while amplifying adaptive immunity (amplifying T-cell activity, B-cell activity and antibody titres) plus stimulating fibroblast-mediated tissue repair and regeneration.
9. Other Medical Applications of Ezrin Peptides
Once ezrin peptide products are available on international markets, starting with our “one-stop” STI treatment, we shall perform additional clinical trials to broaden the indications to other therapies. Ezrin peptides have been demonstrated to stop inflammation and ulceration in all parts of the gut (including ulcerative colitis). Ezrin peptides are effective treatment for diabetic ulcers. Ezrin peptides are effective treatment for ionising radiation injury. Ezrin peptides stop inflammatory respiratory infections including COVID. Ezrin peptides are effective treatment for Hepatitis B, HCV and other inflammatory hepatitis infections. The combined market for all ezrin peptide therapeutic applications exceeds 100 billion dollars.
10. Ezrin Peptide Treatment for Respiratory Infections plus acute & Long COVID.
Ezrin peptides are effective treatment for Influenza A, RSV, parainfluenza and other acute inflammatory lung infections as spray inhaled therapy. Ezrin peptides have been used to effectively treat the inflammatory problems of acute COVID and the adaptive immune amplification properties of ezrin peptides lead to up-regulation of effective natural immunity protection to SARS-CoV-2 re-infection. Dr Holms published a peer reviewed paper in Immuno on the TLR4-RAGE loop mechanism of Long COVID (attached). Recent work on ezrin peptide RepG3 has revealed that ezrin peptides provide symptom relief for both Long COVID and COVID vaccine injury. See my YouTube interview on Trial Site News: https://www.youtube.com/watch?v=i85Rp1aOzF8&t=25s
11. Ezrin Peptide Treatment of Hepatitis
Ezrin peptides have been used clinically in the successful treatment of hepatitis B and HCV. Ezrin peptides increase anti-body titres during HepB vaccination.
12. Ezrin Peptide Treatment for Chronic Inflammatory Diseases
Ezrin peptides have been clinically demonstrated to have applications in the treatment of age-related chronic inflammatory diseases. Ezrin peptides have been used clinically to effectively treat ulcerative colitis and generally any inflammation and ulceration anywhere in the gut. Ezrin peptides also reduce the long term relapse rate of stomach and duodenal ulcers. Ezrin peptides have applications in age-related inflammatory diseases such as arthritis.
13. Ezrin Peptide Treatment of Cancer
We also have animal data on the safety and efficacy of ezrin peptides in animal models of implanted tumours (Sarcoma and Cervical Cancer) and anecdotal clinical evidence of cancer treatment in patients.
14. Ezrin Peptide Treatment of Radiation Damage
Ezrin peptides have also been used clinically to help recovery from ionising radiation injury from tumour radiotherapy, which unfortunately may have to be an active research project in future, due to the increased risk of nuclear war.
15. Dr Rupert Holms: Inventor of ezrin peptide therapeutics
Dr Holms reverse-engineered ezrin peptides from HIV, when he discovered that the c-terminus of HIV gp120 mimics the Alpha domain of human ezrin and this mimicry is
mutation-stable, indicating functionality. The human immune system was hacked by HIV to control immune functions beneficial to its life-cycle.
Dr Holms launched Generation-1 ezrin peptide HEP-1 (brand name Gepon) on the Russian market in 2001. Dr Holms managed a broad clinical development program over 25 years, which demonstrated the safety and the broad range of therapeutic medical applications for ezrin peptides.
After more than 23 clinical trials in Russia, we have a medical revolution of a safe one-stop product for treating any Sexually Transmitted Infection (whether of viral, bacterial, fungal or protozoan origin) as well as a surprisingly wide range of other treatment applications.
16. Dr Rupert Holms: Founder and Executive Chairman of Nearmedic
Dr Rupert Holms founded, financed and managed Nearmedic Group, a profitable and growing bio-pharmaceutical company in the Russian Federation, for 32 years up to 2021.
Dr Holms established Nearmedic at the Gamaleya Institute Moscow in 1989 (in the last years of the Soviet Union). Between 1995 to 1997, he collected investment capital through his City of London connections ( Dr Holms used to be a life science investment manager at Lombard Odier) and received US$10 million of institutional investment from equity funds.
Between 1997 and 2021, Dr Holms developed Nearmedic into a successful award-winning pharmaceutical company in the Russian Federation. Nearmedic grew to a profitable 120 million euro turnover business ( in Russian Roubles), with more than 1000 employees.
Nearmedic launched four pharmaceuticals on the Russian pharmaceutical market: Human Ezrin Peptide One (HEP-1, Brand name “Gepon”) a synthetic peptide which inhibits pro-inflammatory cytokine expression while amplifying adaptive immunity. The second product was a powerful innate TLR4 agonist (a pattern recognition receptor stimulator) derived from potato polysaccharide (Brand name “Immunomax”). The third product was a synthetic polymer used as an influenza vaccine adjuvant (Brand name “Polyoxidonium). The fourth product was an oral immunomodulator derived from cotton polysaccharide (Brand name “Kagocel”) which is an award winning and top selling product on the Russian OTC pharmaceutical market.
17. NewalR&D EIS Private Placing: pre-money £13.1m, raise £5m
NewalR&D closed a SEED funding round in August 2022 and is now seeking to raise Series A funds: the target is to raise a minimum of £5 million product development funding at a pre-money value of £13.1 million.
Please suggest a time for a conversation with you.
I look forward to hearing from you.
Best Wishes
Dr Rupert Holms

Medical & Sciences